Premium
Breakthrough venous thromboembolic events in five patients with COVID‐19 on direct oral anticoagulants
Author(s) -
Lewis Paul,
Tharp Jennifer L.
Publication year - 2021
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13311
Subject(s) - medicine , atrial fibrillation , covid-19 , venous thromboembolism , intensive care medicine , stroke (engine) , d dimer , apixaban , disease , venous thromboembolic disease , rivaroxaban , pulmonary embolism , warfarin , thrombosis , infectious disease (medical specialty) , pathology , mechanical engineering , outbreak , engineering
What is known and objective Coronavirus disease 2019 (COVID‐19) is associated with increased risk of venous thromboembolism (VTE). Guidance for VTE prophylaxis continues to evolve, including addressing direct oral anticoagulants (DOACs) continued upon hospitalization. Case summaries We present 5 patients hospitalized for COVID‐19 while on DOACs. Four patients had atrial fibrillation and had a previous VTE. Four patients developed acute VTE and one developed stroke‐like symptoms. Monitoring D‐dimer assisted with the detection of VTE. Three patients died, and two were discharged alive. What is new and conclusion Therapeutic failure with DOACs appears to be commonplace in COVID‐19. Further research is needed to determine whether there is an underlying cause to this association.